{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:12:53Z","timestamp":1707523973775},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,23]]},"DOI":"10.7759\/cureus.44012","type":"journal-article","created":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T06:45:22Z","timestamp":1692859522000},"source":"Crossref","is-referenced-by-count":0,"title":["Platelet Additive Solutions as an Alternative Storage Medium of Apheresis Platelets to Reduce ABO Antibody Titer for ABO-Incompatibility Platelet Transfusion"],"prefix":"10.7759","author":[{"given":"Sumaiyah","family":"Adzahar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohd Nazri","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zefarina","family":"Zulkafli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noor Haslina","family":"Mohd Noor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marini","family":"Ramli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shafini","family":"Mohamed Yusoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sien Tzi","family":"Lam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajesh","family":"Deshpande","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wan Zaidah","family":"Abdullah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/jca.21207","article-title":"Current status of additive solutions for platelets","volume":"27","author":"Alhumaidan H","year":"2012","unstructured":"Alhumaidan H, Sweeney J. Current status of additive solutions for platelets. J Clin Apher. 2012, 27:93-8. 10.1002\/jca.21207","journal-title":"J Clin Apher"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1159\/000487513","article-title":"Platelet additive Solutions: a review of the latest developments and their clinical implications","volume":"45","author":"van der Meer PF","year":"2018","unstructured":"van der Meer PF, de Korte D. Platelet additive Solutions: a review of the latest developments and their clinical implications. Transfus Med Hemother. 2018, 45:98-102. 10.1159\/000487513","journal-title":"Transfus Med Hemother"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.4103\/GJTM.GJTM_5_17","article-title":"Apheresis platelets in additive solution: is it a good alternative to conventional group-specific apheresis platelets?","volume":"2","author":"Agrawal A","year":"2017","unstructured":"Agrawal A. Apheresis platelets in additive solution: is it a good alternative to conventional group-specific apheresis platelets? . Global J Transfusion Med. 2017, 2:19-23. 10.4103\/GJTM.GJTM_5_17","journal-title":"Global J Transfusion Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/trf.12498","article-title":"The impact of platelet additive solution apheresis platelets on allergic transfusion reactions and corrected count increment (CME)","volume":"54","author":"Tobian AA","year":"2014","unstructured":"Tobian AA, Fuller AK, Uglik K, et al.. The impact of platelet additive solution apheresis platelets on allergic transfusion reactions and corrected count increment (CME). Transfusion. 2014, 54:1523-9; quiz 1522. 10.1111\/trf.12498","journal-title":"Transfusion"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/trf.15138","article-title":"Evaluating safety and cost-effectiveness of platelets stored in additive solution (PAS-F) as a hemolysis risk mitigation strategy","volume":"59","author":"Pagano MB","year":"2019","unstructured":"Pagano MB, Katchatag BL, Khoobyari S, et al.. Evaluating safety and cost-effectiveness of platelets stored in additive solution (PAS-F) as a hemolysis risk mitigation strategy. Transfusion. 2019, 59:1246-51. 10.1111\/trf.15138","journal-title":"Transfusion"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.15406\/htij.2015.01.00017","article-title":"Evaluation of anti-A and anti-B Alloisogglutinin titer in group O plateletpheresis donors","volume":"1","author":"Lilian K","year":"2015","unstructured":"Lilian K, Bazigou F, Lempesopoulos K, et al.. Evaluation of anti-A and anti-B Alloisogglutinin titer in group O plateletpheresis donors. Hematol Transfus Int J. 2015, 1:76-81. 10.15406\/htij.2015.01.00017","journal-title":"Hematol Transfus Int J"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/trf.12597","article-title":"A comparison of adverse reaction rates for PAS\u2009C versus plasma platelet units","volume":"54","author":"Cohn CS","year":"2014","unstructured":"Cohn CS, Stubbs J, Schwartz J, et al.. A comparison of adverse reaction rates for PAS\u2009C versus plasma platelet units. Transfusion. 2014, 54:1927-34. 10.1111\/trf.12597","journal-title":"Transfusion"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/voxs.12264","article-title":"An update on indications for platelet transfusion","volume":"11","author":"Wood EM","year":"2016","unstructured":"Wood EM, Crighton GL, Estcourt LJ, et al.. An update on indications for platelet transfusion. ISBT Sci Series. 2016, 11:170-6. 10.1111\/voxs.12264","journal-title":"ISBT Sci Series"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/trf.15655","article-title":"ABO-incompatible platelets are associated with increased transfusion reaction rates","volume":"60","author":"Malvik N","year":"2020","unstructured":"Malvik N, Leon J, Schlueter AJ, Wu C, Knudson CM. ABO-incompatible platelets are associated with increased transfusion reaction rates. Transfusion. 2020, 60:285-93. 10.1111\/trf.15655","journal-title":"Transfusion"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.21307\/immunohematology-2020-024","article-title":"Quality improvement with platelet additive solution for safer out-of-group platelet transfusions","volume":"35","author":"Tynuv M","year":"2019","unstructured":"Tynuv M, Flegel WA. Quality improvement with platelet additive solution for safer out-of-group platelet transfusions. Immunohematology. 2019, 35:108-15. 10.21307\/immunohematology-2020-024","journal-title":"Immunohematology"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/trf.14523","article-title":"PAS-C platelets contain less plasma protein, lower anti-A and anti-B titers, and decreased HLA antibody specificities compared to plasma platelets","volume":"58","author":"Weisberg SP","year":"2018","unstructured":"Weisberg SP, Shaz BH, Tumer G, Silliman CC, Kelher MR, Cohn CS. PAS-C platelets contain less plasma protein, lower anti-A and anti-B titers, and decreased HLA antibody specificities compared to plasma platelets. Transfusion. 2018, 58:891-5. 10.1111\/trf.14523","journal-title":"Transfusion"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.htct.2020.03.008","article-title":"Comparison of abo antibody levels in apheresis platelets suspended in platelet additive solution and plasma","volume":"43","author":"Kc G","year":"2021","unstructured":"Kc G, Murugesan M, Nayanar SK, Malodan R, Padmanaban M. Comparison of abo antibody levels in apheresis platelets suspended in platelet additive solution and plasma. Hematol Transfus Cell Ther. 2021, 43:179-84. 10.1016\/j.htct.2020.03.008","journal-title":"Hematol Transfus Cell Ther"},{"key":"ref13","article-title":"Evaluation of anti-A and anti-B Alloisogglutinin titer in group O plateletpheresis donors","volume":"5","author":"Chaudhari C","year":"2017","unstructured":"Chaudhari C, Dighe M, Kothari F, et al.. Evaluation of anti-A and anti-B Alloisogglutinin titer in group O plateletpheresis donors. Int J Res Med. 2017, 5:24-31.","journal-title":"Int J Res Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.4103\/ajts.AJTS_150_17","article-title":"Adding to platelet safety and life: platelet additive solutions","volume":"12","author":"Mathur A","year":"2018","unstructured":"Mathur A, Swamy N, Thapa S, Chakraborthy S, Jagannathan L. Adding to platelet safety and life: platelet additive solutions. Asian J Transfus Sci. 2018, 12:136-40. 10.4103\/ajts.AJTS_150_17","journal-title":"Asian J Transfus Sci"},{"key":"ref15","article-title":"ABO antibodies among group O Thai blood donors","volume":"23","author":"Mavichak PCW","year":"2013","unstructured":"Mavichak PCW, Jintana T, Phuraya O. ABO antibodies among group O Thai blood donors. J Hematol Transfus Med. 2013, 23:203-9.","journal-title":"J Hematol Transfus Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/trf.15240","article-title":"Fatal acute hemolytic transfusion reaction due to anti-B from a platelet apheresis unit stored in platelet additive solution","volume":"59","author":"Balbuena-Merle R","year":"2019","unstructured":"Balbuena-Merle R, West FB, Tormey CA, Hendrickson JE. Fatal acute hemolytic transfusion reaction due to anti-B from a platelet apheresis unit stored in platelet additive solution. Transfusion. 2019, 59:1911-5. 10.1111\/trf.15240","journal-title":"Transfusion"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/171584-platelet-additive-solutions-as-an-alternative-storage-medium-of-apheresis-platelets-to-reduce-abo-antibody-titer-for-abo-incompatibility-platelet-transfusion","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:55:40Z","timestamp":1707508540000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/171584-platelet-additive-solutions-as-an-alternative-storage-medium-of-apheresis-platelets-to-reduce-abo-antibody-titer-for-abo-incompatibility-platelet-transfusion"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,23]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.44012","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8,23]]}}}